Biologics and other targeted therapies are creating opportunities for innovative device solutions to meet the needs of the formulations as well as specific patient groups. These therapies may require lower annual volumes, and the device manufacturing strategy must fit commercial expectations at those volumes. Optimal manufacturing solutions should mitigate risk while meeting the quality, financial, timeline, and patient needs of the product.
